

Dr. Na Ma
Company Editor-in-Chief
World Journal of Clinical Oncology

4 June 2020

Dear Dr. Ma,

Thank you for your letter with the positive comments on our manuscript “Novel molecular targets in hepatocellular carcinoma”, and for the opportunity to submit a revised version. We would also like to thank the reviewers for the valuable comments and suggestions to strengthen this manuscript. We have now amended our manuscript accordingly and the changes that have been incorporated in the revised manuscript. We have also addressed all the queries raised by the reviewers. A point-to-point response is listed as the followings. We hope that the editorial board would consider our revised manuscript favourably and we look forward to hearing from you soon.

Yours faithfully,

Ariel Chow, on behalf of all authors

1. There are no descriptions regarding the results of anti-HCC effect in the animal model or human studies.

Author reply: *Thank you for your comment. As suggested, we have listed the anti-HCC effect in animal model or human studies in Table 1 and Table 2.*

2. Moreover, how those drugs are placed in various guideline of the treatment of HCC is not described

Author reply: *Thank you for your comment and we have described the guideline of the treatment of HCC in the Introduction paragraph.*

3. Language editing certificate was not properly provided. Please upload language certificate of language editing company.

Author reply: *Dr. Iyer Deepak is a native English speaker and Dr Deepak has performed the language proof of this manuscript.*